Loading
A phase 2 trial of BMS-986504 in non-small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) is a phase 2 interventional study registered as NCT06855771 by Bristol-Myers Squibb, with 130 participants planned, started 2025-09-09 and due to reach its primary completion in 2028-12-29. Interventions recorded: BMS-986504.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.